Vistagen Therapeutics (VTGN) Enterprise Value (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Enterprise Value of -$45.4 million for Q1 2026, up 26.5% sequentially from -$61.8 million in Q4 2025, and up 43.59% YoY from -$31.6 million in Q1 2025.
Vistagen Therapeutics (VTGN) Enterprise Value (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Enterprise Value for 15 years, with the latest figure at -$45.4 million in Q1 2026.
- Quarterly Enterprise Value rose 43.59% year-over-year to -$45.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.4 million (up 43.59% YoY) and the FY2026 annual result came in at -$45.4 million, up 43.59% from the prior year.
- Enterprise Value rose to -$45.4 million in Q1 2026 per VTGN's latest filing, from -$61.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$9.6 million in Q2 2023 and troughed at -$126.6 million in Q4 2023.
- A 5-year average of -$65.4 million and a median of -$63.2 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 81.53% in 2023, then slumped 1028.79% in 2024.
- Over 5 years, Enterprise Value stood at -$25.0 million in 2022, then sank by 406.4% to -$126.6 million in 2023, then soared by 30.05% to -$88.6 million in 2024, then surged by 30.25% to -$61.8 million in 2025, then gained by 26.5% to -$45.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$45.4 million, -$61.8 million, and -$77.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -31.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.40 Mn |
| Dec 31, 2025 | -61.77 Mn |
| Sep 30, 2025 | -77.18 Mn |
| Jun 30, 2025 | -63.18 Mn |
| Mar 31, 2025 | -80.48 Mn |
| Dec 31, 2024 | -88.56 Mn |
| Sep 30, 2024 | -97.58 Mn |
| Jun 30, 2024 | -108.36 Mn |
| Mar 31, 2024 | -119.17 Mn |
| Dec 31, 2023 | -126.60 Mn |
| Sep 30, 2023 | -37.61 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -16.64 Mn |
| Dec 31, 2022 | -25.00 Mn |
| Sep 30, 2022 | -35.30 Mn |
| Jun 30, 2022 | -51.99 Mn |
| Mar 31, 2022 | -68.14 Mn |
| Dec 31, 2021 | -83.70 Mn |
| Sep 30, 2021 | -93.60 Mn |
| Jun 30, 2021 | -97.78 Mn |